TRβ-GAL4 Luciferase Reporter HEK293 Cell Line (Thyroid Hormone Receptor β Pathway)
The TRβ-GAL4 Luciferase Reporter HEK293 Cell Line is a HEK293 cell line expressing firefly luciferase under the control of the GAL4 upstream activation sequence (UAS) with constitutive expression of human thyroid receptor β ligand binding domain (TRβ LBD, amino acids 173-461) fused to the DNA binding domain (DBD) of GAL4 (GAL4 DBD). This system allows specific detection of thyroid hormone-induced activation of the thyroid receptor β with low cross-reactivity from other nuclear receptors. This cell line has been validated by stimulation with triiodothyronine (T-3).
Interested in screening and profiling inhibitors, blocking antibodies, or activators of thyroid hormone receptor β without the need to purchase and license the cell line? Check out our Cell Signaling Pathway Screening.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
Materials Required for Cell Culture
Name | Ordering Information |
Thaw Medium 1 | BPS Bioscience #60187 |
Growth Medium 1M | BPS Bioscience #79723 |
Materials Required for Cellular Assay
Name | Ordering Information |
3, 3’, 5-Triiodo-L-thyronine (T-3) | Cayman #16028 |
Assay Medium 6B | BPS Bioscience #82202 |
96-well tissue culture treated white clear-bottom assay plate | Corning #3610 |
384-well tissue culture treated white clear-bottom assay plate | PerkinElmer #6007680 |
ONE-Step™ Luciferase Assay System | BPS Bioscience #60690 |
Luminometer |
The cell line has been screened to confirm the absence of Mycoplasma species.
Thyroid hormones play an important role in growth, development, and metabolism. These are mediated by two different thyroid hormone receptor (TR) isoforms, TRα and TRβ. Thyroid receptors are transcriptional factors that control various genes by interacting with specific co-activators, co-repressors and DNA sequences. In humans, TRα is the predominant form of the thyroid receptor in the heart, brain, and bone while TRβ is mainly expressed in the liver, kidney and brain. Interestingly, it has been shown that the patients with non-alcoholic steatohepatitis (NASH) display lower TRβ expression in the liver, and more importantly, TRβ agonist treatment decreased liver steatosis and circulating lipids as well as showed metabolic benefits in preclinical models of diabetes and obesity.
Paguio A, et al., 2010 Curr Chem Genomics. 4: 43-49.